Medicon Hellas S.A (MEDIC) Fair Value & Analysis
Healthcare · GR · Market cap €12.7M
Fair value as of: Jun 25, 2026
From 26 valuation models · updated 7 days ago
Share price +2.0% over the past month.
Price vs Fair Value (12 months)
12‑month range €2.14 – €2.86 · fair‑value band €5.46 – €15.76 · the €2.86 price screens below the €10.76 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Medicon Hellas S.A (MEDIC) currently trades at €2.86, while our model-based Fair Value estimate is €10.76 — implying the stock looks roughly 276.2% undervalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Medicon Hellas S.A generated revenue of €18.0M at a net margin of 9.7%. Revenue declined 6.0% year over year. It earns a return on equity of 9.2%. The stock trades on a trailing P/E of 16.8. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Medicon Hellas S.A. operates in the diagnostics industry. The company offers instruments, tests, and procedures for public and private hospitals, primary care centers, diagnostic centers, and private laboratories in Greece and internationally. The company distributes various analyzer sysytem for chemistry, immunochemistry and hematology labs, intensive care units, and point-of-care systems. It also produces reagents for various analyzers, such as specific protein and hematology, as well as clinical chemistry reagents comprising control and calibration materials, and tests. In addition, the company engages in the production of cosmetic and skin care products under the Miss Beaute brand name. Further, it develops and sells software for laboratory and medical applications, and supplies IT systems to healthcare providers. Additionally, the company remanufactures and resells chemistry, hematology, blood gas, and immunochemistry analyzers; and provides contract remanufacturing and …
Revenue & earnings trend
FY2018 – FY2022 · reported fiscal years
Medicon Hellas S.A reported revenue of €20.8M in FY2022 versus €13.8M in FY2018, a compound +10.8%/yr. Reported net income was €2.5M in FY2022, compounding +8.5%/yr from FY2018.
Is MEDIC fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| 1276 1276 | HK$57.85 | HK$29.84 | -48% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medicon Hellas S.A (MEDIC) undervalued?
What is the fair value of MEDIC?
What is the quality score of MEDIC?
What is the revenue of Medicon Hellas S.A (MEDIC)?
What is the net profit margin of MEDIC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.